BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zervimesine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zervimesine\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05531656-719@assetmemo.bio
DTSTAMP:20261121T005331Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Zervimesine: Phase 2 readout est. (NCT05531656)
DESCRIPTION:Zervimesine\, phase 2\, Alzheimer's Disease.\nStudy: A Study to
  Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease\n
 Estimated primary completion: 31 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zervimesine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05531656
URL:https://assetmemo.bio/drug/zervimesine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
